Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia
Weekly injections of semaglutide over 26 weeks were more effective than matching placebo in improving glycemic control and weight outcomes in patients with schizophrenia who received clozapine or olanzapine, a randomized trial has found. Participants receiving semaglutide did not experience a disproportionate number of adverse events. Study results were published online Dec. 3, 2025 in JAMA Psychiatry .
Publication Details
- Journal
- The Brown University Psychopharmacology Update
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1002/pu.31414
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00